2024年制药年度研发回顾补充信息图：2023年推出的新活性物质

Annual Review 2024 Supplement:New Active Substances Infographic Insights from our supplemental report onnew active substances launched in 2023 Key Findings Last year was pharma’s second-hottest ever in terms of new activesubstances (NASs) introduced. While the forecast for NAS launches isgenerally fair, there are a few clouds on the horizon in terms of a highPhase II failure rate and a relatively small number of first-in-class drugsamong the NASs launched in 2023. Number of NAS launches by year A total of 91 new active substances (NASs) across 90 products entered themarket during 2023 (one was a fixed-dose combination containing twoNASs). This exceeded 2022’s total by 17 and fell only six short of 2021’srecord haul. However, only 15.4% of the NASs launched in 2023 can beclassified as first in class, compared with 26.7% of those launched in 2022. Top company NAS launch performance The sun shone brightest for Pfizer in terms of NAS launches, withsix making it onto the market in 2023. Biogen’s four NAS launchesput it in second place. But the real surprise was the Chinesecompany SinoCellTech, which had the best launch-to-pipeline sizeratio with three NAS debuts. NAS launches by therapeutic group Anti-infectives accounted for the largest share (27.5%) of 2023’sNAS releases, though 19 of the 25 NASs were vaccines. Anticancerdrugs came in a close second, with a 26.3% share of NASlaunches. With 40.1% of the overall pipeline devoted to oncology,this tepid result suggests the therapeutic area remainsa high risk for R&D. SensoryNeurologicalMusculoskeletalImmunologicalGenitourinaryDermatologicalCardiovascularBlood and ClottingAnti-infectiveAnticancerAlimentary/Metabolic The US remains on top in terms of NAS introductions, with 46.5%of 2023 NAS debuts taking place there, a significant increase from2022’s 32% share. But China is coming on strong, posting 25% of NASfirst launches in 2023, up from 21.6% the year before. Note: some drugs that might have been simultaneously launched in more than one market will have beencounted more than once.Source: Pharmaprojects®, March 2024